Featured Research

from universities, journals, and other organizations

Keeping the flu away: Synthetic protein activates immune system within two hours

Date:
July 6, 2012
Source:
San Diego State University
Summary:
Researchers may have found the secret to helping the immune system fight off the flu before it gets you sick. A new study finds that EP67, a powerful synthetic protein, is able to activate the innate immune system within just two hours of being administered.

Woman suffering from the flu. Scientists may have found the secret to helping the immune system fight off the flu before it gets you sick. A new study finds that EP67, a powerful synthetic protein, is able to activate the innate immune system within just two hours of being administered.
Credit: Warren Goldswain / Fotolia

San Diego State University researchers at the Donald P. Shiley BioScience Center may have found the secret to helping the immune system fight off the flu before it gets you sick.

A new study published July 6 in the Public Library of Science journal PLoS ONE, finds that EP67, a powerful synthetic protein, is able to activate the innate immune system within just two hours of being administered.

Prior to this study, EP67 had been primarily used as an adjuvant for vaccines, something added to the vaccine to help activate the immune response. But Joy Phillips, Ph.D. a lead author of the study with her colleague Sam Sanderson, Ph.D. at the University of Nebraska Medical Center, saw potential for it to work on its own.

"The flu virus is very sneaky and actively keeps the immune system from detecting it for a few days until you are getting symptoms," Phillips said. "Our research showed that by introducing EP67 into the body within 24 hours of exposure to the flu virus caused the immune system to react almost immediately to the threat, well before your body normally would."

Because EP67 doesn't work on the virus but on the immune system itself, it functions the same no matter the flu strain, unlike the influenza vaccine which has to exactly match the currently circulating strain.

Phillips said while this study focuses on the flu, EP67 has the potential to work on other respiratory diseases and fungal infections and could have huge potential for emergency therapeutics.

"When you find out you've been exposed to the flu, the only treatments available now target the virus directly but they are not reliable and often the virus develops a resistance against them," Phillips said. "EP67 could potentially be a therapeutic that someone would take when they know they've been exposed that would help the body fight off the virus before you get sick."

It could even be used in the event of a new strain of infectious disease, before the actual pathogen has been identified, as in SARS or the 2009 H1N1 influenza outbreak, Phillips said.

Right now, the testing has been done primarily in mice by infecting them with a flu virus. Those that were given a dose of EP67 within 24 hours of the infection didn't get sick (or as sick) as those that were not treated with EP67.

The level of illness in mice is measured by weight loss. Typically, mice lose approximately 20 percent of their weight when they are infected with the flu but mice treated with EP67 lost an average of just six percent. More importantly, mice who were treated a day after being infected with a lethal dose of influenza did not die, Phillips said.

She said there are also huge implications for veterinary applications, since EP67 is active in animals, including birds.

Future research will examine the effect EP67 has in the presence of a number of other pathogens and to look closer at exactly how EP67 functions within different cells in the body.


Story Source:

The above story is based on materials provided by San Diego State University. Note: Materials may be edited for content and length.


Journal Reference:

  1. Sam D. Sanderson, Marilyn L. Thoman, Kornelia Kis, Elizabeth L. Virts, Edgar B. Herrera, Stephanie Widmann, Homero Sepulveda, Joy A. Phillips. Innate Immune Induction and Influenza Protection Elicited by a Response-Selective Agonist of Human C5a. PLoS ONE, 2012; 7 (7): e40303 DOI: 10.1371/journal.pone.0040303

Cite This Page:

San Diego State University. "Keeping the flu away: Synthetic protein activates immune system within two hours." ScienceDaily. ScienceDaily, 6 July 2012. <www.sciencedaily.com/releases/2012/07/120706234740.htm>.
San Diego State University. (2012, July 6). Keeping the flu away: Synthetic protein activates immune system within two hours. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2012/07/120706234740.htm
San Diego State University. "Keeping the flu away: Synthetic protein activates immune system within two hours." ScienceDaily. www.sciencedaily.com/releases/2012/07/120706234740.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins